Core Insights - CytoSorbents Corporation honors the legacy of Dr. Robert Hawes Bartlett, a pivotal figure in critical care medicine and former Chief Medical Officer, who passed away at age 86 [1][2] - Dr. Bartlett was instrumental in the development and clinical trials of CytoSorb®, a blood purification technology that has been used to treat severe conditions, including during the COVID-19 pandemic [1][3] - The company is advancing its investigational device, DrugSorb™-ATR, aimed at reducing perioperative bleeding in high-risk surgeries [5][6] Company Overview - CytoSorbents Corporation specializes in blood purification technologies for life-threatening conditions in intensive care and cardiac surgery [3] - The company's lead product, CytoSorb®, is approved in the European Union and has been used in nearly 300,000 procedures globally [4] - CytoSorbents is developing additional products, including DrugSorb™-ATR, which has received FDA Breakthrough Device Designations for specific anticoagulant removals [5][6] Contributions of Dr. Bartlett - Dr. Bartlett is recognized as the father of extracorporeal membrane oxygenation (ECMO), a technology that has saved over 100,000 lives worldwide [1][2] - His work included leading clinical trials that supported the approval of CytoSorb® and expanding its use in critical care settings [1][2] - Dr. Bartlett's vision included the combination of CytoSorb with ECMO to enhance treatment for severe acute respiratory distress syndrome (ARDS) [1][2] Future Directions - The company aims to further develop its technologies and expand regulatory approvals for its products in the U.S. and Canada [5][6] - CytoSorbents is focused on leveraging its blood purification technologies to address critical illnesses that currently have limited treatment options [3][4]